Anterograde axonal transport of AAV2-GDNF in rat basal ganglia

Molecular Therapy

Volumn 19, Issue 5, 2011, Pages 922-927

  Ciesielska, Agnieszka ^a   Mittermeyer, Gabriele ^a   Hadaczek, Piotr ^a   Kells, Adrian P ^a   Forsayeth, John ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS TYPE 2; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; ENTOPEDUNCULAR NUCLEUS; GENE EXPRESSION; GENE TRANSFER; GLOBUS PALLIDUS; MALE; NERVE FIBER TRANSPORT; NONHUMAN; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS; PARKINSONIA; RATTUS;

EID: 79955628980     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.248     Document Type: Article

References (42)

1. Kimura, M & Graybiel, AM (1995). Functions of the Cortico-basal Ganglia Loop, Springer: Tokyo; New York.
2. Gill, SS, Patel, NK, Hotton, GR, O'Sullivan, K, McCarter, R, Bunnage, M et al. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589-595. (Pubitemid 36597106)
3. Lang, AE, Gill, S, Patel, NK, Lozano, A, Nutt, JG, Penn, R et al. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466. (Pubitemid 43358066)
4. Björklund, A, Kirik, D, Rosenblad, C, Georgievska, B, Lundberg, C and Mandel, RJ (2000). Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 886: 82-98.
5. Kordower, JH (2003). In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann Neurol 53 Suppl 3: S120-32; discussion S132.
6. Eberling, JL, Kells, AP, Pivirotto, P, Beyer, J, Bringas, J, Federoff, HJ et al. (2009). Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 20: 511-518.
7. Kells, AP, Eberling, J, Su, X, Pivirotto, P, Bringas, J, Hadaczek, P et al. (2010). Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 30: 9567-9577.
8. Fiandaca, M, Forsayeth, J and Bankiewicz, K (2008). Current status of gene therapy trials for Parkinson's disease. Exp Neurol 209: 51-57.
9. Bjorklund, T and Kordower, JH (2010). Gene therapy for Parkinson's disease. Mov Disord 25 Suppl 1: S161-S173.
10. Feng, LR and Maguire-Zeiss, KA (2010). Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs 24: 177-192.
11. Johnston, LC, Eberling, J, Pivirotto, P, Hadaczek, P, Federoff, HJ, Forsayeth, J et al. (2009). Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 20: 497-510.
12. Herzog, CD, Dass, B, Holden, JE, Stansell, J 3rd, Gasmi, M, Tuszynski, MH et al. (2007). Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 22: 1124-1132. (Pubitemid 47067222)
13. Gash, DM, Zhang, Z and Gerhardt, G (1998). Neuroprotective and neurorestorative properties of GDNF. Ann Neurol 44(3 Suppl 1): S121-S125. (Pubitemid 28423838)
14. Kirik, D, Rosenblad, C, Bjorklund, A and Mandel, RJ (2000). Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20: 4686-4700. (Pubitemid 30396634)
15. Björklund, A, Hökfelt, T and Swanson, LW (1987). Integrated Systems of the CNS. Elsevier: New York.
16. Yu, T, Scully, S, Yu, Y, Fox, GM, Jing, S and Zhou, R (1998). Expression of GDNF family receptor components during development: implications in the mechanisms of interaction. J Neurosci 18: 4684-4696. (Pubitemid 28280177)
17. Brooks, DJ (2004). Neuroimaging in Parkinson's disease. NeuroRx 1: 243-254. (Pubitemid 46613776)
18. Manfredsson, FP, Tumer, N, Erdos, B, Landa, T, Broxson, CS, Sullivan, LF et al. (2009). Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 17: 980-991.
19. Passini, MA, Macauley, SL, Huff, MR, Taksir, TV, Bu, J, Wu, IH et al. (2005). AAV vectormediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol Ther 11: 754-762. (Pubitemid 40567980)
20. Kaspar, BK, Lladó, J, Sherkat, N, Rothstein, JD and Gage, FH (2003). Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301: 839-842. (Pubitemid 36962626)
21. Hollis, ER 2nd, Jamshidi, P, Lorenzana, AO, Lee, JK, Gray, SJ, Samulski, RJ et al. (2010). Transient demyelination increases the efficiency of retrograde AAV transduction. Mol Ther 18: 1496-1500.
22. Arvidsson, A, Kirik, D, Lundberg, C, Mandel, RJ, Andsberg, G, Kokaia, Z et al. (2003). Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats. Neurobiol Dis 14: 542-556. (Pubitemid 37543532)
23. Hadaczek, P, Mirek, H, Bringas, J, Cunningham, J and Bankiewicz, K (2004). Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain. Hum Gene Ther 15: 469-479. (Pubitemid 38639618)
24. Kells, AP, Hadaczek, P, Yin, D, Bringas, J, Varenika, V, Forsayeth, J et al. (2009). Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci USA 106: 2407-2411.
25. Young, AB and Penney, JB (1993). Biochemical and functional organization of the basal ganglia. In: Jankovic, J and Tolosa, E (eds). Parkinson's Disease and Movement Disorders. Williams and Wilkins: Baltimore, MD.
26. Thomas, CE, Storm, TA, Huang, Z and Kay, MA (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 78: 3110-3122. (Pubitemid 38314369)
27. Bankiewicz, KS, Eberling, JL, Kohutnicka, M, Jagust, W, Pivirotto, P, Bringas, J et al. (2000). Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using prodrug approach. Exp Neurol 164: 2-14. (Pubitemid 30490717)
28. Bankiewicz, KS, Daadi, M, Pivirotto, P, Bringas, J, Sanftner, L, Cunningham, J et al. (2006). Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp Neurol 197: 363-372. (Pubitemid 43077144)
29. Forsayeth, JR, Eberling, JL, Sanftner, LM, Zhen, Z, Pivirotto, P, Bringas, J et al. (2006). A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther 14: 571-577. (Pubitemid 44296089)
30. Bankiewicz, KS, Forsayeth, J, Eberling, JL, Sanchez-Pernaute, R, Pivirotto, P, Bringas, J et al. (2006). Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14: 564-570. (Pubitemid 44296090)
31. Christine, CW, Starr, PA, Larson, PS, Eberling, JL, Jagust, WJ, Hawkins, RA et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73: 1662-1669.
32. Cunningham, J, Oiwa, Y, Nagy, D, Podsakoff, G, Colosi, P and Bankiewicz, KS (2000). Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant 9: 585-594. (Pubitemid 32002567)
33. Hadaczek, P, Kohutnicka, M, Krauze, MT, Bringas, J, Pivirotto, P, Cunningham, J et al. (2006). Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 17: 291-302.
34. Cunningham, J, Pivirotto, P, Bringas, J, Suzuki, B, Vijay, S, Sanftner, L et al. (2008). Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther 16: 1267-1275. (Pubitemid 351866058)
35. Salegio, EA, Kells, AP, Richardson, RM, Hadaczek, P, Forsayeth, J, Bringas, J et al. (2010). Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders. Hum Gene Ther 21: 1093-1103.
36. Eberling, JL, Jagust, WJ, Christine, CW, Starr, P, Larson, P, Bankiewicz, KS et al. (2008). Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70: 1980-1983.
37. Su, X, Kells, AP, Huang, EJ, Lee, HS, Hadaczek, P, Beyer, J et al. (2009). Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 20: 1627-1640.
38. Paxinos, G and Watson, C (1982). The Rat Brain in Stereotaxic Coordinates. Academic Press: Sydney; New York.
39. Yin, D, Forsayeth, J and Bankiewicz, KS (2010). Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods 187: 46-51.
40. Ungerstedt, U (1971). Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367: 69-93.
41. Matsushita, T, Elliger, S, Elliger, C, Podsakoff, G, Villarreal, L, Kurtzman, GJ et al. (1998). Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 5: 938-945. (Pubitemid 28371911)
42. Wright, JF, Qu, G, Tang, C and Sommer, JM (2003). Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Devel 6: 174-178. (Pubitemid 36368371)